文章名稱引用次數(shù)

• Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease10
• Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease9
• Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study7
• Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma7
• MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool6
• Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome6
• A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy5
• Mass spectrometry and proteomics in hematology5
• Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications4
• Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights4